Reuters logo
BRIEF-Biotest says Immunogen not to exercise late stage co-development option for US-market with Biotest's antibody-drug conjugate
2017年3月24日 / 早上6点10分 / 6 个月前

BRIEF-Biotest says Immunogen not to exercise late stage co-development option for US-market with Biotest's antibody-drug conjugate

March 24 (Reuters) - Biotest AG:

* Immunogen has elected not to exercise its late stage co-development option for the us-market with Biotest’s antibody-drug conjugate (BT-062) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below